# Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection

> **NCT04359680** · PHASE3 · COMPLETED · sponsor: **Romark Laboratories L.C.** · enrollment: 1407 (actual)

## Conditions studied

- COVID-19
- Viral Respiratory Illnesses

## Interventions

- **DRUG:** Nitazoxanide
- **DRUG:** Placebo
- **DIETARY_SUPPLEMENT:** Vitamin Super B-Complex

## Key facts

- **NCT ID:** NCT04359680
- **Lead sponsor:** Romark Laboratories L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-13
- **Primary completion:** 2021-04-07
- **Final completion:** 2021-04-07
- **Target enrollment:** 1407 (ACTUAL)
- **Last updated:** 2024-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04359680

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04359680, "Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04359680. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*